skip to main content

    Updated Visitor Guidelines

 

MENU

 

How to make cancer prevention more equitable

Programs and services aimed at helping people reduce their risk of cancer don’t always meet the needs of people from diverse communities and cultures.

Training Tomorrow's Cancer Leaders

Rogel’s summer training programs expose students early on to cancer career options, hoping to foster a passion for the field and lifelong connections.

A Path of Hope for Glioblastoma Treatment

While brain cancers are not always lethal, the most common form, glioblastoma, is aggressive and incurable, with a median survival of one and a half years. A team of researchers, foundations, and families have pushed Rogel to the forefront as a hub for cutting-edge brain cancer research.

Histotripsy: Making the Impossible Possible

A surprising discovery in graduate school led U-M biomedical engineer Zhen Xu to the first non-invasive, non-thermal tumor resection technique using ultrasound. Twenty years later, she and a team of Rogel researchers have received FDA approval to treat patients with liver cancer. Here’s how they did it.

Improving cancer health equity involves everyone

Equity in cancer care has long been an important theme for Lori Pierce, M.D. She made it a focus as president of the American Society of Clinical Oncology in 2021. So when the editors of The Cancer Journal selected health equity in cancer care as the topic for a recent special issue, Pierce, professor of radiation oncology at Michigan Medicine, was the ideal choice for guest editor.

Reenergizing hospital staff through interactive recharge rooms

Recently, Michigan Medicine became the first health care system in the Midwest to bring Recharge Rooms to its employees. These innovative, immersive mental health interventions were designed to support the well-being and resilience of the hospital’s health care workers.

Why does cancer immunotherapy cause colitis in some patients?

Researchers at the University of Michigan Health Rogel Cancer Center have identified a mechanism that causes severe gastrointestinal problems with immune-based cancer treatment. They also found a way to deliver immunotherapy’s cancer-killing impact without the unwelcome side effect.

Pierce elected to AACR 2024 Class of Fellows of the AACR Academy

Lori J. Pierce, M.D., was one of 30 cancer scientists elected to the American Association for Cancer Research class of Fellows of the AACR Academy. Pierce was elected for illuminating contributions to establishing radiotherapy in the multimodality treatment of breast cancer, including intensity-modulated radiotherapy for node-positive breast cancer and incorporation of radiosensitizing agents, which have collectively resulted in improved treatment outcomes for breast cancer patients, most notably those harboring BRCA1/2 gene mutations.

Pages